593 related articles for article (PubMed ID: 33189630)
1. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
2. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
[TBL] [Abstract][Full Text] [Related]
3. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life Outcomes in PARADIGM-HF.
Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K
Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD
JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523
[TBL] [Abstract][Full Text] [Related]
8. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
9. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Eur J Heart Fail; 2020 Nov; 22(11):2018-2025. PubMed ID: 32946164
[TBL] [Abstract][Full Text] [Related]
10. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
[TBL] [Abstract][Full Text] [Related]
13. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
[TBL] [Abstract][Full Text] [Related]
14. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E;
J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758
[TBL] [Abstract][Full Text] [Related]
16. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
Chen F; Tian G; Bai X; Li J; Yuan Z
Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
[TBL] [Abstract][Full Text] [Related]
17. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
19. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
[TBL] [Abstract][Full Text] [Related]
20. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
